Biotechnology
Commented by Nico Popp on December 22nd, 2021 | 13:50 CET
BioNTech, Novavax, Cardiol Therapeutics: This pandemic profiteer is as cheap as can be
Omicron is coming; that much seems certain. But what does the virus mean for the stock market? Currently, the forecasts of the modelers are dominating the news. While some see it as scaremongering, others consider epidemiological models a rational approximation of what we face. Like a crystal ball, so to speak, but without the hocus-pocus. To assess the situation as an investor, it makes sense to assume neither the best nor the worst. We analyze the current viral situation and explain what this could mean for typical Corona stocks.
Read
Commented by Armin Schulz on December 15th, 2021 | 11:35 CET
Valneva, XPhyto Therapeutics, Pfizer - Corona is far from defeated
In an interview, new Health Minister Karl Lauterbach said, "We will not succeed in defeating Corona completely in the foreseeable period." By period, he probably means his term, which is four years. Thus, the hope that arose in the middle of the year related to a quick end by vaccination seems to have been dashed. The new Omicron variant cannot yet be fully assessed. It is causing uncertainty on the stock markets, which puts renewed pressure on companies that have already suffered from Corona. On the other hand, there are also the profiteers who are fighting Corona. Today we analyze three of these potential profiteers.
Read
Commented by Carsten Mainitz on December 8th, 2021 | 12:53 CET
Pfizer, Defence Therapeutics, Novavax - Who will benefit from Omicron?
The world is trembling before the new Corona variant Omicron. Stock exchanges are going down, panic reigns in the crypto markets and politicians are outbidding each other with calls for tighter lockdown regulations. However, some experienced epidemiologists already see the emergence of Omicron as an indication of an imminent change from pandemic to endemic, in which we will live with the Coronavirus as if it were the flu. However, everyone agrees on one thing: we will still need vaccination. Who is this good news for?
Read
Commented by Stefan Feulner on December 3rd, 2021 | 12:38 CET
BioNTech, Defence Therapeutics, QIAGEN - End in sight?
The federal and state governments have met and decided on a de facto lockdown for the unvaccinated. In the future, only vaccinated and recovered people will be allowed to shop in retail stores. The same applies to cinemas, theaters and restaurants. In addition, the unvaccinated will have to accept contact restrictions. According to the outgoing chancellor, this is an "act of national solidarity" and is necessary to get out of the current difficult situation - hard times, which the Omicron variant has just exacerbated. But according to US strategists, it is precisely the newly emerged mutant that could signal the approaching end of the Corona pandemic.
Read
Commented by Fabian Lorenz on November 25th, 2021 | 12:44 CET
BioNTech, Valneva, Cardiol Therapeutics: Vaccination boosters also share boosters?
The Corona pandemic has been with us all for a good 18 months now, and there is no end in sight. While the industrialized countries are boosting their vaccines, large parts of the world's population have still not been vaccinated for the first time. That means that shares of manufacturers of vaccines or drugs against COVID-19 will continue to be the focus of investors. Driven by the booster and mandatory vaccination discussions, BioNTech has left the correction behind, and the share is marching towards EUR 300. Drug developer Cardiol Therapeutics should now pick up again after the successful capital increase. In any event, analysts see price potential. Vaccine developer Valneva benefits from the EU order but has not yet recovered from Tuesday's "flash crash".
Read
Commented by Nico Popp on November 24th, 2021 | 12:41 CET
BioNTech, Defence Therapeutics, Novavax: Another step towards vaccination against cancer
In Portugal and Spain, vaccination rates are higher than in Germany. There are various discussions about the reasons for this. One argument is the fact that infant mortality was high in both countries for a long time. Those who still vividly remember the stories of dead or lifelong damaged infants are less likely to think twice when the doctor calls for vaccination. The recent experience with BioNTech and other vaccines could also give a new boost to the willingness to vaccinate. It is, therefore, quite fitting that vaccines against many different diseases are now emerging on the market.
Read
Commented by Armin Schulz on November 19th, 2021 | 11:21 CET
Valneva, Cardiol Therapeutics, Novavax - Is the Corona emergency brake coming?
Today, the Robert Koch Institute reported 65,371 new infections, a new sad record. In Berlin, politicians are currently discussing how to proceed. Abolishing the free tests to increase the pressure on the unvaccinated has proven wrong in retrospect. The fact that booster vaccinations might be necessary was also not considered when the vaccination centers were closed. Now the first state is discussing the next lockdown. If the numbers continue to rise, the emergency brake will be pulled in Berlin sooner or later. In parts of Austria, it is already a reality. We take a look at three possible winners of a lockdown.
Read
Commented by Stefan Feulner on November 15th, 2021 | 10:50 CET
Valneva, XPhyto, NanoRepro - Here we go again
Although around 67.4% of the population in Germany is already fully vaccinated, the infection figures are rising to unprecedented heights. The fourth wave with the highly contagious Delta variant is rolling across the republic. This development must be stopped as quickly as possible. In addition to booster vaccinations, politicians are therefore reintroducing citizen testing as a tool against the spread. For diagnostics companies and providers of rapid tests, this means a boom and further increases in earnings, likely to be reflected in stock market valuations in the near future.
Read
Commented by André Will-Laudien on November 8th, 2021 | 12:08 CET
BioNTech, Moderna, Cardiol Therapeutics, Valneva: COVID-19, the vaccination chaos is perfect!
Now the chaos is perfect. According to studies, the preparation from BioNTech/Pfizer is one of the most effective vaccines against the coronavirus. Hundreds of millions of doses have already been administered worldwide. However, the number of COVID infections is currently through the roof. Even those who have been vaccinated twice are likely still not sufficiently protected against infection. There are also unsettling rumors from BioNTech about irregularities in the conduct of studies during the vaccine's approval. Whether it concerns thereby only "rumors" or "provable facts", the capital investors do not care for the time being. They pressed the sell button and thus sent the entire peer group Adhoc into the basement. We take a closer look at the chaos.
Read
Commented by Stefan Feulner on November 5th, 2021 | 11:22 CET
BioNTech, Sativa Wellness, Merck KGaA - Impressive trend
There is no question that vaccine manufacturers are one of the main winners of the Corona pandemic. The recently presented quarterly figures of Pfizer, BioNTech's partner, show this impressively and suggest that the Mainz-based Company will also announce a sales explosion on November 9. Booster vaccinations are likely to continue this trend. Currently, encouraged by legalization, the cannabis industry is also experiencing a new upswing. Be a part of it from the beginning.
Read